Listen.
Diagnose.
Treat.
Live.
About us
At Precision Cancer Technologies Inc. (PCT) we use data, artificial intelligence and proprietary technologies to predict effective first line cancer treatments with >90% likelihood of success before therapy begins.
Sonotype Dx
A fast, non-invasive ultrasound test done during the patient’s first doctor's visit which predicts with >90% accuracy whether: (i) a tumor is benign or malignant and (ii) if malignant, whether it will respond to standard drug treatment
TEST
Non-invasive Quantitative Ultrasound (QUS) measures acoustical properties of cells that can be discriminated in normal healthy cells and tumors.
PREDICT
Through Artificial Intelligence, data from QUS is used to discriminate between benign and malignant breast lesions as well as predicting if the malignant lesions will or will not respond to Standard of Care (SoC).
TREAT
Standard of care (SOC) treatment will be administered only if predicted to be effective thereby saving dollars that would have been spent on ineffective therapy.
MONITOR
QUS monitoring throughout treatment will track the efficacy of the therapeutic intervention as dying cells have different acoustic properties and spectra. Tracking cell death will enable stopping ineffective treatments early on and realize cost savings secured by transitioning faster to an effective therapy.
Cytotype Dx
Proprietary technology that uses the patient’s biopsy to create an environment in vitro that mimics that of the tumour in vivo to analyze the patient’s tumor sensitivity to hundreds of drugs and drug combinations and predicts an effective treatment plan with a >90% likelihood of success before treatment begins.
TEST
Drug sensitivity assessment of the tumour cells focuses specifically on those cells that drive the growth and spread of the tumor.
Automation enables testing the tumor killing effectiveness of >1,000 drug/drug combinations in 2-4 days
PREDICT
Proprietary AI enables selection of the most effective drug/drug combination - before therapeutic intervention - with >90% accuracy
TREAT
The identified drug/drug combination is administered to the patient
MONITOR
SonoType Dx is utilized to track the efficacy of the therapeutic intervention